Screener
Agios Pharmaceuticals AGIO Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Operating lease assets | 23,875 | 30,454 |
| Property and equipment, net | 9,946 | 10,775 |
| Other non-current assets | 9,681 | 3,931 |
| Total assets | $1,108,424 | $1,297,225 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $16,345 | $18,355 |
| Accrued expenses | 34,647 | 45,459 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's total assets?
- Agios Pharmaceuticals (AGIO) reported total assets of $1.11B in Q2 2026.
- How has Agios Pharmaceuticals's total assets changed year-over-year?
- Agios Pharmaceuticals's total assets decreased by 24.7% year-over-year, from $1.47B to $1.11B.
- What is the long-term trend for Agios Pharmaceuticals's total assets?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's total assets has grown at a 8.7% compound annual growth rate (CAGR), from $852.95M to $1.3B.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Agios Pharmaceuticals's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude